INDIA: Natco pushes for additional compulsory licenses

Natco Pharma Ltd has requested the government to grant it a compulsory license for two drugs:

Sutent [Sunitinib], a renal cancer drug from Pfizer &

Tarceva [Erlotinib], a lung cancer medication from Roche.

For more details, read the Mint article [linked above].

Earlier post on Natco’s compulsory license application for Erlotinib, here.